From: Pipeline progress and portfolio management of the top 30 pharma companies over the past two decades
Indications | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CARD | 7 | 12 | 26 | 33 | 48 | 74 | 56 | 68 | 59 | 43 | 52 | 42 | 20 | 42 | 31 | 17 | 22 | 14 | 11 | 11 | 9 |
DERM | 1 | 1 | 5 | 9 | 18 | 10 | 8 | 15 | 17 | 13 | 19 | 19 | 16 | 24 | 19 | 26 | 30 | 19 | 36 | 40 | 22 |
HAEM | 1 | 3 | 11 | 4 | 16 | 16 | 19 | 21 | 33 | 25 | 15 | 10 | 11 | 10 | 15 | 8 | 15 | 9 | 11 | 7 | 4 |
HORM | 1 | 2 | 0 | 1 | 2 | 1 | 3 | 1 | 3 | 1 | 3 | 0 | 2 | 2 | 2 | 1 | 0 | 1 | 0 | 0 | 2 |
INFEC | 9 | 15 | 27 | 46 | 45 | 77 | 114 | 108 | 95 | 110 | 94 | 99 | 92 | 75 | 91 | 84 | 52 | 34 | 40 | 26 | 31 |
META | 14 | 36 | 69 | 74 | 98 | 101 | 154 | 123 | 138 | 137 | 164 | 127 | 132 | 112 | 101 | 67 | 85 | 82 | 73 | 63 | 43 |
MUSCO | 2 | 6 | 10 | 20 | 35 | 28 | 29 | 32 | 25 | 23 | 30 | 15 | 18 | 24 | 21 | 18 | 17 | 10 | 10 | 11 | 5 |
NEURO | 15 | 25 | 52 | 88 | 136 | 110 | 154 | 161 | 150 | 132 | 128 | 106 | 78 | 62 | 61 | 52 | 36 | 34 | 54 | 37 | 45 |
ONCIM | 20 | 25 | 56 | 84 | 96 | 147 | 192 | 196 | 200 | 207 | 193 | 203 | 159 | 150 | 153 | 115 | 129 | 102 | 112 | 94 | 87 |
PARA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RESP | 5 | 7 | 31 | 26 | 38 | 54 | 52 | 76 | 69 | 65 | 83 | 74 | 85 | 65 | 62 | 49 | 39 | 45 | 17 | 17 | 10 |
SENS | 3 | 3 | 10 | 13 | 17 | 21 | 17 | 19 | 32 | 17 | 29 | 16 | 15 | 14 | 19 | 10 | 7 | 3 | 4 | 5 | 4 |
URO | 7 | 2 | 8 | 29 | 27 | 37 | 20 | 29 | 28 | 31 | 23 | 25 | 15 | 14 | 10 | 13 | 10 | 10 | 9 | 5 | 7 |
VAR | 3 | 2 | 6 | 8 | 8 | 12 | 16 | 11 | 34 | 20 | 13 | 14 | 16 | 10 | 9 | 14 | 3 | 8 | 10 | 3 | 5 |